MicroRNAs in metabolism and metabolic disorders

Nature Reviews Molecular Cell Biology

Volumn 13, Issue 4, 2012, Pages 239-251

  Rottiers, Veerle ^a,b   Näär, Anders M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 DEHYDROCHOLESTEROL REDUCTASE; ABC TRANSPORTER A1; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; CHOLESTEROL; FATTY ACID SYNTHASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE 1; LOW DENSITY LIPOPROTEIN; MICRORNA; MICRORNA 103; MICRORNA 106B; MICRORNA 107; MICRORNA 122; MICRORNA 124A; MICRORNA 193B; MICRORNA 223; MICRORNA 33A; MICRORNA 33B; MICRORNA 365; MICRORNA 375; MICRORNA 758; MIRAVIRSEN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ADAPTOR PROTEIN; INSULIN RECEPTOR SUBSTRATE 2; LIVER X RECEPTOR; PANTOTHENATE KINASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SPHINGOMYELIN; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ADIPOCYTE; ADIPOGENESIS; ANTISENSE THERAPY; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DRUG TARGETING; ENERGY METABOLISM; EXOCYTOSIS; FATTY ACID OXIDATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; INTRON; LIPOGENESIS; LIVER LEVEL; METABOLIC DISORDER; METABOLIC SYNDROME X; MUSCLE DEVELOPMENT; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PARACRINE SIGNALING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION; ADIPOSE TISSUE; ATHEROSCLEROSIS; CAENORHABDITIS ELEGANS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL MEMBRANE; COLON CANCER; DEACETYLATION; DISEASE ASSOCIATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FATTY LIVER; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; IN VIVO STUDY; LIPID METABOLISM; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; SIGNAL TRANSDUCTION; VIRUS RESISTANCE;

CHOLESTEROL; ENDOCRINE SYSTEM; FATTY LIVER; GLUCOSE; HOMEOSTASIS; HUMANS; INSULIN; LIPID METABOLISM; METABOLIC DISEASES; METABOLIC SYNDROME X; MICRORNAS; OBESITY; OLIGORIBONUCLEOTIDES, ANTISENSE; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 84858776574     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm3313     Document Type: Review

References (148)

1. Lehrke, M. & Lazar, M. A. The many faces of PPARγ. Cell 123, 993-999 (2005).
2. Zelcer, N. & Tontonoz, P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116, 607-614 (2006). (Pubitemid 43326865)
3. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131 (2002). (Pubitemid 34496588)
4. Nakae, J., Oki, M. & Cao, Y. The FoxO transcription factors and metabolic regulation. FEBS Lett. 582, 54-67 (2008). (Pubitemid 350297245)
5. Uyeda, K. & Repa, J. J. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 4, 107-110 (2006). (Pubitemid 44138720)
6. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
7. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
8. Voinnet, O. Origin, biogenesis, and activity of plant microRNAs. Cell 136, 669-687 (2009).
9. Fabian, M. R. et al. Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol. Cell 35, 868-880 (2009).
10. Grimson, A. et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91-105 (2007). (Pubitemid 46991392)
11. Betel, D., Wilson, M., Gabow, A., Marks, D. S. & Sander, C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 36, D149-D153 (2008). (Pubitemid 351149712)
12. Krek, A. et al. Combinatorial microRNA target predictions. Nature Genet. 37, 495-500 (2005). (Pubitemid 40617277)
13. Hon, L. S. & Zhang, Z. The roles of binding site arrangement and combinatorial targeting in microRNA repression of gene expression. Genome Biol. 8, R166 (2007).
14. Rottiers, V. et al. MicroRNAs in metabolism and metabolic diseases. Cold Spring Harb. Symp. Quant. Biol. 12 Dec 2011 (doi:10.1101/sqb.2011.76.011049).
15. Tsang, J., Zhu, J. & van Oudenaarden, A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol. Cell 26, 753-767 (2007). (Pubitemid 46856248)
16. Raghow, R., Yellaturu, C., Deng, X., Park, E. A. & Elam, M. B. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol. Metab. 19, 65-73 (2008). (Pubitemid 351317897)
17. Cornier, M. A. et al. The metabolic syndrome. Endocr. Rev. 29, 777-822 (2008).
18. Angulo, P. Obesity and nonalcoholic fatty liver disease. Nutr. Rev. 65, S57-S63 (2007).
19. Lewis, A. P. & Jopling, C. L. Regulation and biological function of the liver-specific miR-122. Biochem. Soc. Trans. 38, 1553-1557 (2010).
20. Esau, C. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87-98 (2006).
21. Krutzfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689 (2005).
22. Veedu, R. N. & Wengel, J. Locked nucleic acid as a novel class of therapeutic agents. RNA Biol. 6, 321-323 (2009).
23. Elmen, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008). (Pubitemid 351550859)
24. Elmen, J. et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153-1162 (2008). (Pubitemid 351330933)
25. Iliopoulos, D., Drosatos, K., Hiyama, Y., Goldberg, I. J. & Zannis, V. I. MicroRNA-370 controls the expression of microRNA-122 and Cpt1α and affects lipid metabolism. J. Lipid Res. 51, 1513-1523 (2010).
26. Coulouarn, C., Factor, V. M., Andersen, J. B., Durkin, M. E. & Thorgeirsson, S. S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28, 3526-3536 (2009).
27. Bai, S. et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 284, 32015-32027 (2009).
28. Jopling, C. L., Schutz, S. & Sarnow, P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 4, 77-85 (2008). (Pubitemid 351944051)
29. Norman, K. L. & Sarnow, P. Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J. Virol. 84, 666-670 (2010).
30. Roberts, A. P., Lewis, A. P. & Jopling, C. L. miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res. 39, 7716-7729 (2011).
31. Gerin, I. et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J. Biol. Chem. 285, 33652-33661 (2010).
32. Horie, T. et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc. Natl Acad. Sci. USA 107, 17321-17326 (2010).
33. Marquart, T. J., Allen, R. M., Ory, D. S. & Baldan, A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc. Natl Acad. Sci. USA 107, 12228-12232 (2010).
34. Najafi-Shoushtari, S. H. et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328, 1566-1569 (2010).
35. Rayner, K. J. et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328, 1570-1573 (2010).
36. Davalos, A. et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc. Natl Acad. Sci. USA 108, 9232-9237 (2011).
37. Tang, C. & Oram, J. F. The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim. Biophys. Acta 1791, 563-572 (2009).
38. Rye, K. A., Bursill, C. A., Lambert, G., Tabet, F. & Barter, P. J. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50, S195-S200 (2009).
39. Rayner, K. J. et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Invest. 121, 2921-2931 (2011).
40. Brown, M. S., Ye, J. & Goldstein, J. L. Medicine. HDL miR-ed down by SREBP introns. Science 328, 1495-1496 (2010).
41. Rayner, K. J. et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478, 404-407 (2011).
42. Ramirez, C. M. et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler. Thromb. Vasc. Biol. 31, 2707-2714 (2011).
43. Kim, J. et al. miR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression. Exp. Neurol. 18 Nov 2011 (doi:10.1016/j. expneurol.2011.11.010).
44. Mostoslavsky, R. et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124, 315-329 (2006). (Pubitemid 43121980)
45. Michishita, E. et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452, 492-496 (2008). (Pubitemid 351450840)
46. Xiao, C. et al. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J. Biol. Chem. 285, 36776-36784 (2010).
47. Zhong, L. et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hifα. Cell 140, 280-293 (2010).
48. Kim, H. S. et al. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. 12, 224-236 (2010).
49. Hardie, D. G. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem. Soc. Trans. 39, 1-13 (2011).
50. Yap, F., Craddock, L. & Yang, J. Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription. Int. J. Biol. Sci. 7, 645-650 (2011).
51. Li, Y. et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13, 376-388 (2011).
52. Matsumoto, M. et al. Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. Diabetes 51, 1672-1680 (2002). (Pubitemid 34564277)
53. Taniguchi, C. M., Ueki, K. & Kahn, R. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J. Clin. Invest. 115, 718-727 (2005). (Pubitemid 40322247)
54. Tobe, K. et al. Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2-/-mouse liver. J. Biol. Chem. 276, 38337-38340 (2001).
55. Kohjima, M. et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int. J. Mol. Med. 21, 507-511 (2008). (Pubitemid 351802646)
56. Guay, C., Roggli, E., Nesca, V., Jacovetti, C. & Regazzi, R. Diabetes mellitus, a microRNA-related disease? Transl. Res. 157, 253-264 (2011).
57. Herman, M. A. & Kahn, B. B. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J. Clin. Invest. 116, 1767-1775 (2006). (Pubitemid 44033296)
58. Siddle, K. Signalling by insulin and IGF receptors: supporting acts and new players. J. Mol. Endocrinol. 47, R1-R10 (2011).
59. Leavens, K. F. & Birnbaum, M. J. Insulin signaling to hepatic lipid metabolism in health and disease. Crit. Rev. Biochem. Mol. Biol. 46, 200-215 (2011).
60. Osborne, T. F. & Espenshade, P. J. Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it's been. Genes Dev. 23, 2578-2591 (2009).
61. Kloosterman, W. P., Lagendijk, A. K., Ketting, R. F., Moulton, J. D. & Plasterk, R. H. Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol. 5, e203 (2007).
62. Poy, M. N. et al. miR-375 maintains normal pancreatic α-and β-cell mass. Proc. Natl Acad. Sci. USA 106, 5813-5818 (2009).
63. Poy, M. N. et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432, 226-230 (2004). (Pubitemid 39545853)
64. El Ouaamari, A. et al. miR-375 targets 3′-phosphoinositide- dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic β-cells. Diabetes 57, 2708-2717 (2008).
65. Baroukh, N. N. & Van Obberghen, E. Function of microRNA-375 and microRNA-124a in pancreas and brain. FEBS J. 276, 6509-6521 (2009).
66. Baroukh, N. et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic β-cell lines. J. Biol. Chem. 282, 19575-19588 (2007). (Pubitemid 47100119)
67. Lovis, P., Gattesco, S. & Regazzi, R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol. Chem. 389, 305-312 (2008). (Pubitemid 351329024)
68. Ramachandran, D. et al. Sirt1 and mir-9 expression is regulated during glucose-stimulated insulin secretion in pancreatic β-islets. FEBS J. 278, 1167-1174 (2011).
69. Plaisance, V. et al. MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J. Biol. Chem. 281, 26932-26942 (2006). (Pubitemid 44401722)
70. Pullen, T. J., da Silva Xavier, G., Kelsey, G. & Rutter, G. A. miR-29a and miR-29b contribute to pancreatic β-cell-specific silencing of monocarboxylate transporter 1 (Mct1). Mol. Cell. Biol. 31, 3182-3194 (2011).
71. He, A., Zhu, L., Gupta, N., Chang, Y. & Fang, F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol. Endocrinol. 21, 2785-2794 (2007). (Pubitemid 350035159)
72. Kim, S. & Pak, Y. Caveolin-2 regulation of the cell cycle in response to insulin in Hirc-B fibroblast cells. Biochem. Biophys. Res. Commun. 330, 88-96 (2005). (Pubitemid 40394939)
73. Pandey, A. K. et al. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol. Cell. Endocrinol. 332, 125-133 (2011).
74. Ryu, H. S., Park, S. Y., Ma, D., Zhang, J. & Lee, W. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS ONE 6, e17343 (2011).
75. Lu, H., Buchan, R. J. & Cook, S. A. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc. Res. 86, 410-420 (2010).
76. Esguerra, J. L., Bolmeson, C., Cilio, C. M. & Eliasson, L. Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model Goto-Kakizaki rat. PLoS ONE 6, e18613 (2011).
77. Jordan, S. D. et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nature Cell Biol. 13, 434-446 (2011).
78. Li, S. et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J. Lipid Res. 50, 1756-1765 (2009).
79. Nakanishi, N. et al. The up-regulation of microRNA-335 is associated with lipid metabolism in liver and white adipose tissue of genetically obese mice. Biochem. Biophys. Res. Commun. 385, 492-496 (2009).
80. Takanabe, R. et al. Up-regulated expression of microRNA-143 in association with obesity in adipose tissue of mice fed high-fat diet. Biochem. Biophys. Res. Commun. 376, 728-732 (2008).
81. Trajkovski, M. et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474, 649-653 (2011).
82. Xie, H., Lim, B. & Lodish, H. F. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 58, 1050-1057 (2009).
83. Wilfred, B. R., Wang, W. X. & Nelson, P. T. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol. Genet. Metab. 91, 209-217 (2007). (Pubitemid 46819124)
84. Naar, A. M. MiRs with a sweet tooth. Cell Metab. 14, 149-150 (2011).
85. Martello, G. et al. A MicroRNA targeting dicer for metastasis control. Cell 141, 1195-1207 (2010).
86. Morita, S. et al. Dicer is required for maintaining adult pancreas. PLoS ONE 4, e4212 (2009).
87. Lynn, F. C. et al. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes 56, 2938-2945 (2007). (Pubitemid 350223628)
88. Lovis, P. et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic β-cell dysfunction. Diabetes 57, 2728-2736 (2008).
89. Roggli, E. et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic β-cells. Diabetes 59, 978-986 (2010).
90. Yamakuchi, M. & Lowenstein, C. J. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8, 712-715 (2009).
91. Zhu, H. et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 147, 81-94 (2011).
92. Lefterova, M. I. & Lazar, M. A. New developments in adipogenesis. Trends Endocrinol. Metab. 20, 107-114 (2009).
93. Alexander, R., Lodish, H. & Sun, L. MicroRNAs in adipogenesis and as therapeutic targets for obesity. Expert Opin. Ther. Targets 15, 623-636 (2011).
94. Esau, C. et al. MicroRNA-143 regulates adipocyte differentiation. J. Biol. Chem. 279, 52361-52365 (2004). (Pubitemid 39656612)
95. Romao, J. M. et al. MicroRNA regulation in mammalian adipogenesis. Exp. Biol. Med. (Maywood) 236, 997-1004 (2011).
96. Cypess, A. M. et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509-1517 (2009).
97. Sun, L. et al. Mir193b-365 is essential for brown fat differentiation. Nature Cell Biol. 13, 958-965 (2011).
98. Kloting, N. et al. MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS ONE 4, e4699 (2009).
99. Heneghan, H. M., Miller, N., McAnena, O. J., O'Brien, T. & Kerin, M. J. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J. Clin. Endocrinol. Metab. 96, e846-e850 (2011).
100. Ortega, F. J. et al. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS ONE 5, e9022 (2010).
101. Cheung, O. et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 48, 1810-1820 (2008).
102. Cermelli, S., Ruggieri, A., Marrero, J. A., Ioannou, G. N. & Beretta, L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 6, e23937 (2011).
103. Kong, L. et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 48, 61-69 (2011).
104. Lee, J. & Kemper, J. K. Controlling SIRT1 expression by microRNAs in health and metabolic disease. Aging (Albany NY) 2, 527-534 (2010).
105. Kemper, J. K. et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10, 392-404 (2009).
106. Li, X. et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28, 91-106 (2007). (Pubitemid 47531974)
107. Motta, M. C. et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 116, 551-563 (2004). (Pubitemid 38264432)
108. Ponugoti, B. et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J. Biol. Chem. 285, 33959-33970 (2010).
109. Purushotham, A. et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9, 327-338 (2009).
110. Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159 (2001). (Pubitemid 33035942)
111. Walker, A. K. et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholester ol regulator SREBP. Genes Dev. 24, 1403-1417 (2010).
112. Yeung, F. et al. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23, 2369-2380 (2004). (Pubitemid 38954844)
113. Yamakuchi, M., Ferlito, M. & Lowenstein, C. J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl Acad. Sci. USA 105, 13421-13426 (2008).
114. Lee, J. et al. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. J. Biol. Chem. 285, 12604-12611 (2010).
115. Chang, T. C. et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26, 745-752 (2007).
116. He, L. et al. A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134 (2007). (Pubitemid 47014436)
117. Raver-Shapira, N. et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 26, 731-743 (2007). (Pubitemid 46856247)
118. Tarasov, V. et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6, 1586-1593 (2007). (Pubitemid 47327945)
119. Milne, J. C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712-716 (2007). (Pubitemid 350207685)
120. Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342 (2006). (Pubitemid 44764104)
121. Feige, J. N. et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 8, 347-358 (2008).
122. Chen, X., Liang, H., Zhang, J., Zen, K. & Zhang, C. Y. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 22, 125-132 (2012).
123. Creemers, E. E., Tijsen, A. J. & Pinto, Y. M. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ. Res. 110, 483-495 (2012).
124. Hunter, M. P. et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 3, e3694 (2008).
125. Arroyo, J. D. et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA 108, 5003-5008 (2011).
126. Turchinovich, A., Weiz, L., Langheinz, A. & Burwinkel, B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 39, 7223-7233 (2011).
127. Wang, K., Zhang, S., Weber, J., Baxter, D. & Galas, D. J. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 38, 7248-7259 (2010).
128. Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D. & Remaley, A. T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature Cell Biol. 13, 423-433 (2011).
129. Zampetaki, A. et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 107, 810-817 (2010).
130. Li, S. et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 124, 175-184 (2011).
131. Kosaka, N. et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 285, 17442-17452 (2010).
132. Bagamasbad, P. & Denver, R. J. Mechanisms and significance of nuclear receptor auto-and cross-regulation. Gen. Comp. Endocrinol. 170, 3-17 (2011).
133. Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biol. 9, 654-659 (2007). (Pubitemid 47214727)
134. Yang, J. S. & Lai, E. C. Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol. Cell 43, 892-903 (2011).
135. Herker, E. & Ott, M. Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol. Metab. 22, 241-248 (2011).
136. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
137. Stenvang, J., Petri, A., Lindow, M., Obad, S. & Kauppinen, S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 3, 1 (2012).
138. Laudadio, I. et al. A feedback loop between the liver-enriched transcription factor network and Mir-122 controls hepatocyte differentiation. Gastroenterology 142, 119-129 (2012).
139. Chang, J. et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 1, 106-113 (2004).
140. Tsai, W. C. et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49, 1571-1582 (2009).
141. Lin, Q., Gao, Z., Alarcon, R. M., Ye, J. & Yun, Z. A role of miR-27 in the regulation of adipogenesis. FEBS J. 276, 2348-2358 (2009).
142. Kim, S. Y. et al. miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARγ expression. Biochem. Biophys. Res. Commun. 392, 323-328 (2010).
143. Li, W. Q. et al. The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS J. 278, 1522-1532 (2011).
144. Gerin, I. et al. Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis. Am. J. Physiol. Endocrinol. Metab. 299, e198-e206 (2010).
145. Jin, W., Dodson, M. V., Moore, S. S., Basarab, J. A. & Guan, L. L. Characterization of microRNA expression in bovine adipose tissues: a potential regulatory mechanism of subcutaneous adipose tissue development. BMC Mol. Biol. 11, 29 (2010).
146. Eichner, L. J. et al. miR-378* mediates metabolic shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. Cell Metab. 12, 352-361 (2010).
147. Lee, E. K. et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor γ expression. Mol. Cell. Biol. 31, 626-638 (2011).
148. Sun, T., Fu, M., Bookout, A. L., Kliewer, S. A. & Mangelsdorf, D. J. MicroRNA let-7 regulates 3T3-L1 adipogenesis. Mol. Endocrinol. 23, 925-931 (2009).